Mrk stock forecast the latest MRK stock forecast shows

The latest MRK stock forecast shows steady upside momentum, with analysts revising 12-month targets to $130–$135 amid robust Q1 earnings and strong pharmaceutical pipeline growth, particularly in oncology. Trading volume remains above its 30-day average, suggesting institutional accumulation. Another key factor, in his view, was the promising development of sac-TMT, an antibody-drug conjugate for advanced non-small cell lung cancer, which received ‘Breakthrough Therapy Designation’ from the FDA. This could accelerate its market entry and strengthen the company’s valuation. Additionally, the analyst thinks that Merck’s financial outlook remains strong, with expected net income growth and lower patent expiry risks compared to peers. Merck’s Animal Health business is a key contributor to its top-line growth, as Merck is recording above-market growth. A short-term MRK stock forecast shows a potential test of the $128 resistance level if broader healthcare sector indices continue outperforming the S&P